| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 5 | 2023 | 363 | 2.710 |
Why?
|
| Respiratory Tract Diseases | 2 | 2023 | 25 | 1.790 |
Why?
|
| Neoplasms | 14 | 2022 | 1033 | 1.720 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 143 | 1.530 |
Why?
|
| Cannabis | 2 | 2023 | 75 | 1.470 |
Why?
|
| Smoking | 14 | 2021 | 903 | 1.460 |
Why?
|
| Quality of Life | 10 | 2020 | 459 | 1.400 |
Why?
|
| Mesothelioma | 9 | 2023 | 135 | 1.350 |
Why?
|
| Urinary Bladder Neoplasms | 7 | 2023 | 63 | 1.280 |
Why?
|
| Breast Neoplasms | 25 | 2023 | 1426 | 1.280 |
Why?
|
| Survivors | 7 | 2021 | 126 | 1.240 |
Why?
|
| Respiration Disorders | 2 | 2023 | 10 | 1.110 |
Why?
|
| Humans | 106 | 2023 | 34853 | 1.040 |
Why?
|
| Mammography | 14 | 2014 | 176 | 0.990 |
Why?
|
| Adolescent Behavior | 5 | 2021 | 243 | 0.980 |
Why?
|
| Areca | 2 | 2020 | 27 | 0.920 |
Why?
|
| Female | 78 | 2023 | 19873 | 0.870 |
Why?
|
| Hawaii | 31 | 2023 | 1878 | 0.860 |
Why?
|
| HMGB1 Protein | 5 | 2023 | 29 | 0.860 |
Why?
|
| Information Seeking Behavior | 1 | 2020 | 23 | 0.750 |
Why?
|
| Marijuana Smoking | 1 | 2021 | 82 | 0.750 |
Why?
|
| Adolescent | 22 | 2023 | 5035 | 0.680 |
Why?
|
| Acculturation | 1 | 2020 | 172 | 0.680 |
Why?
|
| Male | 44 | 2021 | 18870 | 0.660 |
Why?
|
| Middle Aged | 48 | 2022 | 9642 | 0.640 |
Why?
|
| Aged | 35 | 2021 | 6448 | 0.630 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 3 | 2023 | 22 | 0.630 |
Why?
|
| Exercise | 2 | 2019 | 524 | 0.630 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 292 | 0.620 |
Why?
|
| Asbestos | 3 | 2023 | 47 | 0.600 |
Why?
|
| Adult | 42 | 2022 | 11034 | 0.570 |
Why?
|
| Cross-Sectional Studies | 12 | 2021 | 2561 | 0.530 |
Why?
|
| Body Composition | 3 | 2021 | 146 | 0.530 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 790 | 0.510 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 336 | 0.490 |
Why?
|
| Breast | 6 | 2014 | 134 | 0.480 |
Why?
|
| Premenopause | 9 | 2013 | 103 | 0.480 |
Why?
|
| Risk Factors | 23 | 2023 | 3414 | 0.470 |
Why?
|
| Attitude to Health | 3 | 2020 | 311 | 0.430 |
Why?
|
| Nipple Aspirate Fluid | 4 | 2013 | 14 | 0.430 |
Why?
|
| Complementary Therapies | 2 | 2012 | 45 | 0.420 |
Why?
|
| Young Adult | 15 | 2022 | 4012 | 0.420 |
Why?
|
| Soy Foods | 4 | 2013 | 59 | 0.410 |
Why?
|
| Whole Body Imaging | 2 | 2021 | 25 | 0.390 |
Why?
|
| Micronesia | 2 | 2020 | 87 | 0.380 |
Why?
|
| Sickness Impact Profile | 2 | 2007 | 20 | 0.360 |
Why?
|
| Aged, 80 and over | 13 | 2021 | 2333 | 0.340 |
Why?
|
| Psychometrics | 3 | 2020 | 292 | 0.330 |
Why?
|
| Telemedicine | 2 | 2021 | 163 | 0.320 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2023 | 48 | 0.320 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2007 | 14 | 0.320 |
Why?
|
| Anthropometry | 4 | 2021 | 91 | 0.310 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2018 | 30 | 0.310 |
Why?
|
| Aid to Families with Dependent Children | 1 | 2007 | 1 | 0.310 |
Why?
|
| Colonic Neoplasms | 2 | 2020 | 181 | 0.300 |
Why?
|
| Morinda | 2 | 2021 | 9 | 0.290 |
Why?
|
| Health Behavior | 5 | 2020 | 491 | 0.290 |
Why?
|
| Neoplasm Staging | 10 | 2021 | 269 | 0.290 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2017 | 243 | 0.280 |
Why?
|
| Breast Feeding | 1 | 2007 | 105 | 0.280 |
Why?
|
| Absorptiometry, Photon | 3 | 2021 | 73 | 0.270 |
Why?
|
| Students | 4 | 2017 | 452 | 0.270 |
Why?
|
| Prognosis | 9 | 2021 | 707 | 0.270 |
Why?
|
| Menthol | 2 | 2015 | 21 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 781 | 0.260 |
Why?
|
| Isoflavones | 5 | 2012 | 125 | 0.250 |
Why?
|
| Cultural Diversity | 2 | 2002 | 158 | 0.250 |
Why?
|
| United States | 7 | 2021 | 3894 | 0.250 |
Why?
|
| Caregivers | 3 | 2021 | 167 | 0.250 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 2 | 2022 | 3 | 0.240 |
Why?
|
| Adaptation, Psychological | 3 | 2017 | 358 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 206 | 0.230 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 794 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 528 | 0.220 |
Why?
|
| Quality of Health Care | 2 | 2021 | 136 | 0.220 |
Why?
|
| Age Factors | 7 | 2019 | 1007 | 0.220 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2023 | 81 | 0.210 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2019 | 89 | 0.210 |
Why?
|
| BCG Vaccine | 1 | 2022 | 9 | 0.210 |
Why?
|
| Prevalence | 10 | 2019 | 1425 | 0.210 |
Why?
|
| Adipose Tissue | 2 | 2021 | 167 | 0.210 |
Why?
|
| Carotenoids | 2 | 2014 | 70 | 0.210 |
Why?
|
| California | 1 | 2023 | 436 | 0.210 |
Why?
|
| Pilot Projects | 6 | 2022 | 628 | 0.210 |
Why?
|
| Prospective Studies | 5 | 2019 | 1353 | 0.210 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 901 | 0.200 |
Why?
|
| Receptor, erbB-2 | 2 | 2023 | 122 | 0.200 |
Why?
|
| Asbestosis | 1 | 2020 | 6 | 0.200 |
Why?
|
| Postmenopause | 5 | 2014 | 125 | 0.200 |
Why?
|
| Health Surveys | 2 | 2020 | 358 | 0.190 |
Why?
|
| Health Literacy | 1 | 2022 | 100 | 0.190 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 51 | 0.190 |
Why?
|
| Uveal Neoplasms | 1 | 2020 | 8 | 0.190 |
Why?
|
| Receptors, Calcitriol | 1 | 2021 | 59 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 638 | 0.190 |
Why?
|
| RecQ Helicases | 1 | 2020 | 35 | 0.190 |
Why?
|
| Activities of Daily Living | 2 | 2013 | 104 | 0.190 |
Why?
|
| Philippines | 5 | 2015 | 72 | 0.190 |
Why?
|
| Estrogens | 2 | 2012 | 190 | 0.190 |
Why?
|
| Knee | 1 | 2019 | 8 | 0.190 |
Why?
|
| Japan | 7 | 2012 | 296 | 0.180 |
Why?
|
| Dance Therapy | 1 | 2019 | 5 | 0.180 |
Why?
|
| Health Status Indicators | 2 | 2013 | 73 | 0.180 |
Why?
|
| Parity | 2 | 2012 | 46 | 0.180 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 65 | 0.180 |
Why?
|
| Population Surveillance | 5 | 2012 | 231 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 178 | 0.180 |
Why?
|
| Registries | 5 | 2017 | 330 | 0.180 |
Why?
|
| Vitamin D | 2 | 2013 | 176 | 0.180 |
Why?
|
| Melanoma | 1 | 2020 | 91 | 0.170 |
Why?
|
| Interleukin-15 | 1 | 2019 | 13 | 0.170 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2011 | 9 | 0.170 |
Why?
|
| Nicotine | 3 | 2018 | 238 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 133 | 0.170 |
Why?
|
| Estrone | 2 | 2011 | 21 | 0.170 |
Why?
|
| Fatigue | 2 | 2017 | 79 | 0.170 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 90 | 0.170 |
Why?
|
| Up-Regulation | 1 | 2021 | 490 | 0.170 |
Why?
|
| Flavoring Agents | 1 | 2018 | 17 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 151 | 0.170 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 147 | 0.170 |
Why?
|
| Cross-Cultural Comparison | 2 | 2013 | 100 | 0.160 |
Why?
|
| Case-Control Studies | 8 | 2014 | 1056 | 0.160 |
Why?
|
| Aldehydes | 1 | 2018 | 65 | 0.160 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 195 | 0.160 |
Why?
|
| Receptors, Progesterone | 2 | 2011 | 78 | 0.160 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 413 | 0.160 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 1003 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 303 | 0.150 |
Why?
|
| Pyruvates | 1 | 2017 | 5 | 0.150 |
Why?
|
| Receptors, Estrogen | 2 | 2011 | 145 | 0.150 |
Why?
|
| Soybean Proteins | 3 | 2011 | 38 | 0.150 |
Why?
|
| Risk-Taking | 1 | 2020 | 435 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 9 | 0.150 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 17 | 0.150 |
Why?
|
| Estradiol | 2 | 2011 | 244 | 0.150 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 52 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2023 | 184 | 0.140 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2016 | 47 | 0.140 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2016 | 26 | 0.140 |
Why?
|
| Mutation | 4 | 2023 | 1023 | 0.140 |
Why?
|
| Proteins | 1 | 2019 | 352 | 0.140 |
Why?
|
| Behavior, Addictive | 1 | 2016 | 33 | 0.140 |
Why?
|
| Diet | 5 | 2013 | 747 | 0.140 |
Why?
|
| Pleural Neoplasms | 1 | 2016 | 51 | 0.130 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 13 | 0.130 |
Why?
|
| Animals | 9 | 2023 | 14307 | 0.130 |
Why?
|
| Time Factors | 6 | 2011 | 1681 | 0.130 |
Why?
|
| Perception | 3 | 2021 | 183 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2015 | 23 | 0.130 |
Why?
|
| Infant | 4 | 2015 | 1014 | 0.130 |
Why?
|
| Cross-Over Studies | 5 | 2013 | 102 | 0.130 |
Why?
|
| Ubiquinone | 1 | 2014 | 21 | 0.120 |
Why?
|
| Motivation | 1 | 2017 | 415 | 0.120 |
Why?
|
| Mice | 6 | 2023 | 5668 | 0.120 |
Why?
|
| Tocopherols | 1 | 2014 | 62 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2016 | 207 | 0.120 |
Why?
|
| Vitamin A | 1 | 2014 | 87 | 0.120 |
Why?
|
| Vitamins | 1 | 2014 | 91 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2020 | 1961 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 247 | 0.110 |
Why?
|
| Survival Rate | 4 | 2011 | 310 | 0.110 |
Why?
|
| Fetal Blood | 1 | 2013 | 47 | 0.110 |
Why?
|
| Mammary Glands, Human | 1 | 2013 | 39 | 0.110 |
Why?
|
| Physical Fitness | 1 | 2013 | 78 | 0.110 |
Why?
|
| Antibody Affinity | 1 | 2012 | 25 | 0.110 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2012 | 12 | 0.110 |
Why?
|
| Pregnancy | 4 | 2013 | 1503 | 0.110 |
Why?
|
| Child | 4 | 2019 | 2875 | 0.110 |
Why?
|
| Reproductive History | 1 | 2012 | 18 | 0.110 |
Why?
|
| Cause of Death | 1 | 2012 | 154 | 0.100 |
Why?
|
| Heterozygote | 2 | 2023 | 91 | 0.100 |
Why?
|
| Antigens, Protozoan | 1 | 2012 | 71 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2017 | 541 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2011 | 1422 | 0.100 |
Why?
|
| Nipples | 1 | 2011 | 14 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 94 | 0.100 |
Why?
|
| Urinalysis | 2 | 2022 | 31 | 0.100 |
Why?
|
| Tobacco Use Disorder | 1 | 2015 | 229 | 0.100 |
Why?
|
| Malaria, Falciparum | 1 | 2012 | 81 | 0.100 |
Why?
|
| Emigrants and Immigrants | 1 | 2013 | 125 | 0.100 |
Why?
|
| Incidence | 5 | 2020 | 882 | 0.100 |
Why?
|
| Schools | 3 | 2017 | 229 | 0.100 |
Why?
|
| Logistic Models | 4 | 2019 | 894 | 0.100 |
Why?
|
| Cell Movement | 3 | 2021 | 545 | 0.100 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 2011 | 35 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2013 | 366 | 0.090 |
Why?
|
| gamma-Tocopherol | 1 | 2010 | 18 | 0.090 |
Why?
|
| Women's Health | 1 | 2011 | 135 | 0.090 |
Why?
|
| Obesity | 2 | 2010 | 965 | 0.090 |
Why?
|
| Adiposity | 1 | 2011 | 145 | 0.090 |
Why?
|
| Motor Activity | 1 | 2013 | 393 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 964 | 0.090 |
Why?
|
| Micronutrients | 1 | 2010 | 42 | 0.090 |
Why?
|
| Nonlinear Dynamics | 2 | 2013 | 30 | 0.090 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 5 | 0.090 |
Why?
|
| Scopoletin | 1 | 2009 | 4 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 147 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2021 | 1149 | 0.090 |
Why?
|
| Regression Analysis | 4 | 2015 | 429 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 841 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 2 | 2022 | 122 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2010 | 202 | 0.080 |
Why?
|
| Leptin | 1 | 2010 | 115 | 0.080 |
Why?
|
| Odds Ratio | 4 | 2015 | 517 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2006 | 424 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 375 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2021 | 322 | 0.080 |
Why?
|
| Phytotherapy | 1 | 2009 | 62 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2019 | 1318 | 0.080 |
Why?
|
| Control Groups | 1 | 2007 | 2 | 0.080 |
Why?
|
| Linear Models | 2 | 2021 | 253 | 0.080 |
Why?
|
| Aging | 1 | 2013 | 639 | 0.080 |
Why?
|
| Sex Factors | 2 | 2019 | 859 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2007 | 22 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2013 | 423 | 0.080 |
Why?
|
| Prolactin | 1 | 2007 | 59 | 0.080 |
Why?
|
| Inflammation | 2 | 2023 | 577 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 2128 | 0.080 |
Why?
|
| Maternal-Child Health Centers | 1 | 2007 | 4 | 0.080 |
Why?
|
| Nursing Research | 1 | 2007 | 12 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 66 | 0.080 |
Why?
|
| Healthy People Programs | 1 | 2007 | 22 | 0.080 |
Why?
|
| Likelihood Functions | 1 | 2007 | 59 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 555 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 203 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 445 | 0.070 |
Why?
|
| Self Efficacy | 2 | 2019 | 173 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2007 | 171 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2007 | 356 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2020 | 897 | 0.070 |
Why?
|
| Feeding Behavior | 2 | 2007 | 418 | 0.070 |
Why?
|
| Internet | 2 | 2017 | 204 | 0.070 |
Why?
|
| Depression | 2 | 2017 | 664 | 0.070 |
Why?
|
| Risk | 2 | 2016 | 256 | 0.070 |
Why?
|
| Cotinine | 2 | 2015 | 40 | 0.070 |
Why?
|
| ROC Curve | 2 | 2021 | 138 | 0.070 |
Why?
|
| Body Mass Index | 4 | 2011 | 775 | 0.070 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 119 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2007 | 490 | 0.060 |
Why?
|
| Progesterone | 1 | 2005 | 117 | 0.060 |
Why?
|
| Life Style | 1 | 2007 | 288 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2005 | 82 | 0.060 |
Why?
|
| Saliva | 2 | 2015 | 97 | 0.060 |
Why?
|
| Demography | 1 | 2004 | 167 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2007 | 871 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2019 | 1349 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 114 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 480 | 0.060 |
Why?
|
| Plant Extracts | 2 | 2021 | 250 | 0.060 |
Why?
|
| Smoking Cessation | 3 | 2018 | 487 | 0.060 |
Why?
|
| Overweight | 1 | 2006 | 233 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2007 | 469 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 1530 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1300 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 17 | 0.060 |
Why?
|
| Models, Psychological | 1 | 2003 | 120 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 17 | 0.060 |
Why?
|
| SEER Program | 1 | 2003 | 87 | 0.060 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2022 | 3 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 20 | 0.060 |
Why?
|
| Sick Role | 1 | 2002 | 6 | 0.050 |
Why?
|
| Administration, Intravesical | 1 | 2022 | 5 | 0.050 |
Why?
|
| Selection Bias | 1 | 2021 | 9 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2003 | 166 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2021 | 10 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 984 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 325 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2021 | 21 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2021 | 11 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 145 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 201 | 0.050 |
Why?
|
| Language | 1 | 2022 | 143 | 0.050 |
Why?
|
| Asbestos, Crocidolite | 1 | 2020 | 8 | 0.050 |
Why?
|
| beta Catenin | 1 | 2021 | 46 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 29 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2021 | 196 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 95 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2020 | 34 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 195 | 0.050 |
Why?
|
| Communication | 1 | 2022 | 170 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2011 | 269 | 0.050 |
Why?
|
| Nitrosamines | 1 | 2020 | 9 | 0.050 |
Why?
|
| Biopsy | 1 | 2020 | 151 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 211 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2019 | 43 | 0.040 |
Why?
|
| Tobacco, Smokeless | 1 | 2019 | 18 | 0.040 |
Why?
|
| Family | 1 | 2020 | 162 | 0.040 |
Why?
|
| Triglycerides | 1 | 2019 | 129 | 0.040 |
Why?
|
| Guam | 1 | 2019 | 76 | 0.040 |
Why?
|
| Mycobacterium bovis | 1 | 2019 | 14 | 0.040 |
Why?
|
| China | 2 | 2012 | 178 | 0.040 |
Why?
|
| Base Sequence | 1 | 2021 | 932 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 307 | 0.040 |
Why?
|
| Fructose | 1 | 2018 | 23 | 0.040 |
Why?
|
| Sucrose | 1 | 2018 | 27 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 217 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2019 | 116 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2019 | 286 | 0.040 |
Why?
|
| Insulin | 1 | 2019 | 224 | 0.040 |
Why?
|
| Mental Health | 1 | 2021 | 270 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 537 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 642 | 0.040 |
Why?
|
| Azoxymethane | 1 | 2017 | 7 | 0.040 |
Why?
|
| Enterocytes | 1 | 2017 | 4 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2017 | 40 | 0.040 |
Why?
|
| Norway | 2 | 2007 | 9 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 254 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 43 | 0.040 |
Why?
|
| Arizona | 2 | 2007 | 92 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2017 | 143 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 92 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 27 | 0.040 |
Why?
|
| Glucose | 1 | 2018 | 217 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2016 | 18 | 0.040 |
Why?
|
| Multigene Family | 1 | 2016 | 105 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 58 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 242 | 0.040 |
Why?
|
| Pleural Effusion | 1 | 2016 | 8 | 0.040 |
Why?
|
| Genome, Human | 1 | 2016 | 112 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 143 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 94 | 0.030 |
Why?
|
| Osteopontin | 1 | 2016 | 35 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 608 | 0.030 |
Why?
|
| Alleles | 1 | 2016 | 284 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 68 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 2015 | 30 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 225 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 649 | 0.030 |
Why?
|
| Cytokines | 1 | 2019 | 569 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2021 | 583 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 213 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2015 | 34 | 0.030 |
Why?
|
| Los Angeles | 2 | 2006 | 368 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 420 | 0.030 |
Why?
|
| Social Behavior | 1 | 2015 | 124 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 198 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 391 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 484 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 255 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 177 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2016 | 301 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2005 | 187 | 0.030 |
Why?
|
| Lactation | 1 | 2013 | 38 | 0.030 |
Why?
|
| Sunlight | 1 | 2013 | 46 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 151 | 0.030 |
Why?
|
| Seasons | 1 | 2013 | 112 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 87 | 0.030 |
Why?
|
| Hydroxyestrones | 1 | 2012 | 8 | 0.030 |
Why?
|
| Korea | 1 | 2012 | 43 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1152 | 0.030 |
Why?
|
| Cognition | 1 | 2015 | 373 | 0.030 |
Why?
|
| Food Analysis | 1 | 2011 | 30 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 66 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 650 | 0.030 |
Why?
|
| Flavonoids | 1 | 2012 | 78 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2011 | 49 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2013 | 196 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 32 | 0.020 |
Why?
|
| Anxiety | 1 | 2017 | 705 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 38 | 0.020 |
Why?
|
| Milk Proteins | 1 | 2010 | 28 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 834 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 859 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 580 | 0.020 |
Why?
|
| Apoptosis | 1 | 2017 | 1317 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 173 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 727 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 1802 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 355 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 608 | 0.020 |
Why?
|
| Pain | 1 | 2009 | 249 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 228 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2005 | 41 | 0.020 |
Why?
|
| Menopause | 1 | 2005 | 54 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 204 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2005 | 15 | 0.020 |
Why?
|
| Mastectomy | 1 | 2005 | 19 | 0.020 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2005 | 52 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 212 | 0.020 |
Why?
|
| Insurance Claim Reporting | 1 | 2003 | 4 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 2003 | 40 | 0.010 |
Why?
|
| Periodicity | 1 | 2003 | 33 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 404 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 570 | 0.010 |
Why?
|
| Affect | 1 | 2003 | 147 | 0.010 |
Why?
|
| Comorbidity | 1 | 2003 | 606 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 756 | 0.010 |
Why?
|